胸膜间皮瘤治疗的免疫疗法：当前和新兴的治疗策略
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies
影响因子:4.90000
分区:生物学3区 / 生化与分子生物学3区 化学：综合3区
发表日期:2024 Oct 09
作者:
Lauren Chiec, Debora S Bruno
摘要
胸膜间皮瘤是与石棉暴露和预后差有关的罕见恶性肿瘤，总体生存率为12％。结果可能会根据诊断和组织学亚型时的阶段而有所不同。最近，利用双检查点抑制剂方案和化学疗法与免疫肿瘤剂结合使用的临床试验显示了结果的影响变化。在本文中，我们回顾了导致在治疗该疾病的临床实践中成功实施免疫疗法的研究，并强调了正在进行的临床试验，探讨了使用不同免疫疗法策略来治疗胸膜间皮瘤。我们还讨论了在间皮瘤和目前正在调查以克服它们的未来策略的背景下，基于免疫疗法的方法的挑战。
Abstract
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune oncologic agents have demonstrated impactful changes in outcomes. In this article, we review studies that have led to the successful implementation of immunotherapy in clinical practice for the treatment of this disease and highlight ongoing clinical trials exploring the use of different immunotherapy strategies for the treatment of pleural mesothelioma. We also discuss the challenges of immunotherapy-based approaches in the context of mesothelioma and future strategies currently being investigated to overcome them.